DME and nAMD Treatment Advances
Explore treatment dosing strategies and next-generation anti-VEGFs for DME and nAMD
Developer: MedLearning2017
App Size: Varies With Device
Release Date: May 7, 2024
Price: Free
Explore treatment dosing strategies and next-generation anti-VEGFs for DME and nAMD
This Immersive Enhanced Reality experience investigates the role of vascular endothelial growth factor (VEGF) in diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD). The program will present strategies for optimizing anti-VEGF treatment regimens, while examining dosing strategies and the incorporation of next-generation anti-VEGF therapies, toward the goal of reducing treatment burden and optimizing outcomes in patients with these retinal conditions.